|Bid||34.72 x 1800|
|Ask||39.40 x 800|
|Day's Range||37.22 - 38.29|
|52 Week Range||25.62 - 129.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.88|
NEW YORK, NY / ACCESSWIRE / September 20, 2018 / Wall Street posted mixed results on Wednesday as tech shares weakened and trade tensions continued to rise. The Dow Jones Industrial Average gained 0.61 ...
WALTHAM, Mass., Sept. 19, 2018-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The Cantor Global Healthcare Conference ...
Tesaro stock popped in bullish fashion Wednesday after the biotech reported an experimental regimen was successful in 64% of lung cancer patients tested.
Today, Tesaro (TSRO) announced the start of the second stage of its JASPER trial. Tesaro is conducting the Phase 2 JASPER trial to evaluate the safety and efficacy of Zejula and an anti-PD-1 antibody combination therapy for the treatment of individuals with NSCLC (non-small cell lung cancer) in a first-line setting. Tesaro decided to go ahead with the trial after Zejula achieved the protocol specified response criteria in the initial group of 16 patients, among whom 14 were evaluable.
On September 4, the European Commission approved the marketing authorization of Puma Biotechnology’s Nerlynx as extended adjuvant therapy for the treatment of adults with early-stage HER2-positive (hormone receptor-2 positive) breast cancer who completed previous adjuvant trastuzumab-containing therapy less than a year ago.
TESARO, Inc. (TSRO), an oncology-focused biopharmaceutical company, today announced it has initiated the second stage of the JASPER study that is designed to assess clinical benefit of ZEJULA® in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer (NSCLC) patients. “These JASPER data provide preliminary evidence that the combination of ZEJULA and an anti-PD-1 antibody could be active as a first-line treatment for patients with non-small cell lung cancer and high levels of PD-L1 expression,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO.
On August 30, Insys Therapeutics (INSY) stock closed at $10.67, a ~34.05% increase from the previous day’s close of $7.96. On August 29, Insys Therapeutics stock closed at $7.96, which was ~94% above its 52-week low of $4.10 on October 31, 2017. Its closing price on August 30 was 31% below its 52-week high of $14.00 on January 3, 2018.
WALTHAM, Mass., Aug. 27, 2018-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. Citi’ s 13 th Annual Biotech Day at ...
Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.
Tesaro (TSRO) generated total revenues of $57.21 million in the second quarter. The company generates revenues from product sales and licensing and collaboration activities. Its product sales are comprised of Zejula and Varubi sales.
Tesaro’s (TSRO) selling, general, and administrative expenses increased from $92.98 million in the second quarter of 2017 to $100.03 million in the second quarter of 2018. The increase was due to higher expenses for salaries, benefits, and other personnel-related costs.
Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.
On August 2, Tesaro (TSRO) reported revenues of ~$57.2 million in the second quarter, which is a rise of ~94.2% YoY (year-over-year). The increase was driven by rising demand for ZEJULA, which reported sales of $54 million in the second quarter. The sales were ~107.7% higher on a YoY basis and 10% higher on a sequential basis. For fiscal 2018, Tesaro expects ZEJULA, which is a leading PARP inhibitor in ovarian cancer indication, to report revenues of $225 million–$235 million. Based on the midpoint of the guidance range, the revenue guidance implies YoY growth of ~111% and sequential growth of 10% for ZEJULA.
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Medical companies Tesaro and Stericycle reported second quarter results last week that sent both stocks tumbling into the red. Both companies lowered their ...
Tesaro stock crashed to a four-year low Friday after the biotech cut its 2018 outlook and analysts suggested its key drug, Zejula, is struggling to gain traction in the U.S.